Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,716.09
(
0.25%
)
US TECH 100
24,130.00
(
0.48%
)
Dow Jones
46,993.26
(
0.10%
)
Brent Oil
100.35
(
-0.30%
)
Bitcoin
74,130.75
(
0.25%
)
News Focus
News Focus
Post# of 257253
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122793
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 146402

Thursday, 08/23/2012 9:34:11 AM

Thursday, August 23, 2012 9:34:11 AM

Post# of 257253
GSK/JNJ start phase-3 RA trials for Sirukumab:

http://www.reuters.com/article/2012/08/23/us-johnsonjohnson-gsk-drugtrial-idUSBRE87M0H420120823

One phase-3 trial is in the second-line setting (following MTX) and one is effectively in the third-line setting (following a TNF-a drug). Both trials have placebo as the comparator, but only the third-line trial has radiographic progression as an endpoint.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now